News & Updates

VIDEO: Apalutamide’s tolerability in prostate cancer patients

Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, discusses apalutamide’s tolerability in prostate cancer patients.

VIDEO: Apalutamide’s tolerability in prostate cancer patients

a day ago

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

31 Mar 2025 by

Therapeutic advancements based on immuno-oncology (IO) combinations have revolutionized the treatment landscape for renal cell carcinoma (RCC). In particular, front-line use of immune checkpoint inhibitors combined with tyrosine kinase inhibitors (TKIs) offers superior survival benefits compared with TKI monotherapy or IO-IO combinations. At the 10^th Annual Scientific Meeting of the Hong Kong Society of Uro-Oncology (HKSUO) (Uro- Oncology Asia 2025), Professor Viktor Grünwald of the University Hospital Essen, Essen, Germany, presented recent data supporting the broad antitumour activity of pembrolizumab plus lenvatinib in patients with clear- and non-clear-cell RCC histologies.

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

31 Mar 2025

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

10 Jan 2025 by

A 45-year-old nonsmoking, non-drinking Chinese male with good past health presented in 2019 with haematuria. He was initially diagnosed with non–muscle invasive urothelial carcinoma (UC) of the bladder. Transurethral resection of bladder tumour (TURBT) was performed in June and August 2019, followed by three courses of intravesical Bacillus Calmette-Guerin between September 2019 and May 2020. His baseline Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 1.

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

10 Jan 2025

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

04 Dec 2024

Landmark analysis of the phase III TITAN study shows that apalutamide plus ADT has resulted in UL PSA in a larger proportion of mHSPC patients than treatment with ADT alone. Furthermore, deeper and earlier UL PSA decline was associated with improved outcomes, including rPFS and OS.

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

04 Dec 2024

Optimizing first-and subsequent-line therapy for advanced RCC

13 Jun 2024 by

The treatment landscape of metastatic renal cell carcinoma (mRCC) has undergone a major transformation in the past two decades, with interleukin-2 and interferon-α being replaced with anti-angiogenic tyrosine kinase inhibitors (TKIs), inhibitors of mammalian target of rapamycin (mTOR) and immune checkpoint inhibitors (ICIs). At an Eisai-sponsored symposium organized by the Hong Kong Society of Uro-Oncology during Uro-Oncology Asia 2024, Professor Sun-Young Rha of the Yonsei University College of Medicine in Seoul, South Korea, discussed the importance of optimizing first-line treatment and subsequent strategies for patients with advanced RCC. Rha also reviewed clinical evidence on regimens containing lenvatinib (Lenvima^®, Eisai), an oral TKI against VEGF receptor, which have been shown to improve outcomes in first and subsequent lines of therapy.

Optimizing first-and subsequent-line therapy for advanced RCC

13 Jun 2024

Second-generation antiandrogen in an elderly patient with high-volume mCSPC and multiple comorbidities

22 May 2024 by

A 75-year-old male presented with frequent urination in January 2023. His prostate-specific antigen (PSA) level was above normal at 54.2 ng/mL. Prostate biopsy yielded a Gleason score of 4 + 3. Prostate-specific membrane antigen (PSMA) PET-CT scan showed multiple bone metastases, with left supraclavicular lymph node (LN) and right external iliac LN uptake. The patient was diagnosed with high-volume metastatic castration-sensitive prostate cancer (mCSPC).

Second-generation antiandrogen in an elderly patient with high-volume mCSPC and multiple comorbidities

22 May 2024

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

14 Jan 2021 by

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

14 Jan 2021

News & Updates

Filter by Specialty:

Specialty:

VIDEO: Apalutamide’s tolerability in prostate cancer patients

VIDEO: Apalutamide’s tolerability in prostate cancer patients

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

Use of maintenance immunotherapy as bladder-preserving therapy in node-positive muscle-invasive urothelial carcinoma

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

[Infographics] Apalutamide in mHSPC: Deep and rapid PSA response correlates with longer rPFS, OS and time to CRPC

Optimizing first-and subsequent-line therapy for advanced RCC

Optimizing first-and subsequent-line therapy for advanced RCC

Second-generation antiandrogen in an elderly patient with high-volume mCSPC and multiple comorbidities

Second-generation antiandrogen in an elderly patient with high-volume mCSPC and multiple comorbidities

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer